BioPharmX Reports Fiscal First Quarter 2020 Financial Results
SAN JOSE, Calif., June 11, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports financial results for the quarter ended April 30, 2019.
Recent Highlights
-- Completed the last patient visit in the Phase 2b clinical trial of
BPX-04(1), a novel topical gel formulation of fully solubilized
minocycline for the treatment of papulopustular rosacea. The company
anticipates announcing topline efficacy and safety data from the study
in early July 2019 pending database lock and results validation.
-- Raised net proceeds of $3.6 million from the sale of common stock in a
registered direct offering.
-- Regained compliance with NYSE American continued listing standards
related to the company's low stock price by effecting a 1-for-25 reverse
stock split.
-- Entered into a Capital on Demand Sales Agreement with JonesTrading
Institutional Services LLC whereby the company may issue common stock
for proceeds up to $8.5 million from time to time through "at the market
offerings."
-- Further reduced operating costs by reducing its workforce by
approximately 20%.
"The company continues to take steps on behalf of its shareholders to advance and to drive value in its topical minocycline programs." said Dr. Tierney, BioPharmX CEO. "As such, we are looking forward to communicating the topline results from our Phase 2b rosacea study."
First Quarter Financial Results
For the first quarter ended April 30, 2019, total operating expenses were $3.6 million, compared with total operating expenses of $4.4 million in the prior fiscal year's first quarter.
Net loss for the quarter ended April 30, 2019 was $3.6 million, or $0.38 per share, compared with a net loss of $4.4 million, or $0.61 per share, during the prior fiscal year's first quarter.
Excluding stock-based compensation expense and the impact of change in fair value of warrant liability, non-GAAP net loss for the quarter ended April 30, 2019 was $3.4 million, or $0.36 per share. During the first quarter of the prior fiscal year, the comparable non-GAAP net loss was $3.7 million, or $0.52 per share.
Cash and cash equivalents, as of April 30, 2019, were $3.3 million.
About BioPharmX® Corporation
BioPharmX Corporation (NYSE American: BPMX) is a specialty pharmaceutical company focused on developing prescription products utilizing its proprietary HyantX Topical Delivery System for dermatology indications. To learn more about BioPharmX, visit www.BioPharmX.com.
Use of Non-GAAP Measures
BioPharmX Corporation has supplemented its financial information prepared in accordance with generally accepted accounting principles in the United States ("GAAP") with non-GAAP measures, including non-GAAP net loss and non-GAAP net loss per share, which do not include stock-based compensation expense and the impact of changes in fair value of warrant liability. The presentation of this additional information is not meant to be considered in isolation or as a substitute for results prepared in accordance with GAAP. Management uses the non-GAAP information internally to evaluate its ongoing business, operational performance and cash requirements and believes these non-GAAP measures are useful to investors as they provide the same basis for evaluating BioPharmX Corporation's performance as applied by management.
BioPharmX Corporation has provided a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure. These non-GAAP measures may be different from non-GAAP measures used by other companies, including peer companies, and therefore, comparability may be limited. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles. BioPharmX Corporation believes that non-GAAP measures have limitations in that they do not reflect all of the amounts associated with its results of operations as determined in accordance with GAAP and that these measures should be considered in addition to, not as a substitute for or in isolation from, measures prepared in accordance with GAAP. BioPharmX Corporation encourages investors and others to review the company's financial information in its entirety and not rely on a single financial measure.
Stock-based compensation expense represents non-cash charges related to equity awards granted by BioPharmX Corporation. The change in fair value of warrant liability results from the periodic revaluing of the warrant liability. These amounts are excluded from the company's non-GAAP net loss and non-GAAP net loss per share because they are not reflective of ongoing operating results in the period incurred. Although these may be recurring charges to BioPharmX Corporation's operations, management believes the measurement of these amounts can vary considerably from period to period and depend substantially on factors that are not a direct consequence of operating performance that is within management's control. Thus, management believes that excluding these charges from non-GAAP net loss and non-GAAP net loss per share facilitates comparisons of BioPharmX Corporation's operational performance in different periods, as well as with similarly determined non-GAAP financial measures of comparable companies.
Forward-Looking Statement
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. This press release contains forward-looking statements about the company's expectations, plans, intentions, and strategies, including, but not limited to the timing to complete the Phase 2b study for BPX-04, the topline results from the company's Phase 2b rosacea study, the company's ability to raise capital under its Capital On Demand Sales Agreement, the commencement and results of future trials for BPX-04, level of operating expenditures, the company's ability to obtain patent protection and defend its intellectual property and the company's ability to regain compliance with the NYSE American LLC's continued listing standards and maintain its listing in the future. Additional risks are set forth in our filings with the Securities and Exchange Commission, including those described in the company's Quarterly Report on Form 10-Q for the quarter ended April 30, 2019. The forward-looking statements included in this press release are made only as of the date hereof, and the company undertakes no obligation to publicly update such statements.
(1)Caution: BPX-04 is a new drug limited by the U.S. law to investigational use only.
BioPharmX and HyantX are registered trademarks of BioPharmX, Inc.
--TABLES TO FOLLOW --
BIOPHARMX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except per share amounts; unaudited)
Three Months Ended
April 30,
2019 2018
Revenues, net
$ - $18
Cost of goods sold - 7
Gross margin - 11
Operating expenses:
Research and
development 2,199 2,327
Sales and
marketing 264 601
General and
administrative 1,177 1,446
Total operating expenses 3,640 4,374
Loss from
operations (3,640) (4,363)
Change in fair value of
warrant liability 9 (66)
Other income, net 10 29
Loss before
provision for
income taxes (3,621) (4,400)
Provision for
income taxes 2 2
Net and comprehensive loss $(3,623) $(4,402)
Net loss per share
Basic and
diluted ($0.38) ($0.61)
Shares used in computing net loss per share
Basic and
diluted 9,433 7,189
BIOPHARMX CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, unaudited)
April 30, January 31,
2019 2019
Assets
Current assets:
Cash and cash
equivalents $3,283 $3,069
Prepaid expenses
and other 250 316
Total current assets 3,533 3,385
Property and
equipment, net 140 148
Operating lease
right-of-use
asset 1,136
Other 121 121
Total assets $4,930 $3,654
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable $1,185 $1,363
Accrued expenses
and other 1,346 934
Total current liabilities 2,531 2,297
Long-term
liabilities 975 59
Total liabilities 3,506 2,356
Stockholders' equity 1,424 1,298
Total liabilities and
stockholders' equity $4,930 $3,654
BIOPHARMX CORPORATION
Reconciliation of GAAP Net Loss to Non-GAAP Net Loss
(in thousands, except per share amounts; unaudited)
Three Months Ended
April 30,
2019 2018
GAAP net loss
available to common
stockholders $(3,623) $(4,402)
Change in fair
value of warrant
liability (9) 66
Stock-based
compensation
expense:
Research and development 103 200
Sales and marketing 21 129
General and administrative 67 264
Total stock-based compensation
expense 191 593
Total reconciling
items 182 659
Non-GAAP net loss
available to common
stockholders $(3,441) $(3,743)
GAAP net loss
available to common
stockholders $(0.38) $(0.61)
Reconciling items
Change in fair value of warrant
liability 0.01
Stock-based compensation expense 0.02 0.08
Non-GAAP net loss
per share: basic and
diluted $(0.36) $(0.52)
Shares used in
computing non-GAAP
net loss per share
Basic and diluted 9,433 7,189
View original content to download multimedia:http://www.prnewswire.com/news-releases/biopharmx-reports-fiscal-first-quarter-2020-financial-results-300864831.html
SOURCE BioPharmX Corporation
